Human Interferon Alpha2a as Anti Hepatitis B and C
Abstract: Hepatitis is an
inflammation of the liver mainly caused by hepatitis viruses. There are 5
different types of hepatitis based on the infecting virus; A, B, C, D and E.
Hepatitis B and C are chronic diseases that potentially develop into
hepatocarcinoma and cirrhosis on unappropriate treatments. World Health
Organization (WHO) stated that currently 350 million people worldwide are
living with chronic hepatitis B and 150 million people are living with
Hepatitis C. The mortality rate in the world due to hepatitis is about 1.5
million people per year. The human interferon alpha2a (hIFNα2a) is a therapeutic
protein used as therapeutic protein for hepatitis B and C. This review
discusses the hepatitis B (HBV) and C (HCV) viruses, mechanisms of hIFNα2a as
antivirus through signal transduction pathway and improvement of hIFNα2a
properties by protein modification. The application of recombinant hIFNα2a
(rhIFNα2a) in the treatment of hepatitis B and C that recommended by European
Association for The Study of Liver (EASL) and the viral resistance mechanism
are also included. The status of hepatitis B and C and the development of
rhIFNα2a is also described as well.
Keywords: Antiviral,
hepatitis, human interferon alpha2a, protein modification, viral resistance
Penulis: Ratih A. Ningrum
Kode Jurnal: jpfarmasidd170028
